The SURMOUNT-5 trial demonstrated superior weight loss with tirzepatide compared to semaglutide at 72 weeks
Dihydroberberine (DHB) is a metabolite of berberine thats naturally formed in the gut and absorbed more easily (5x more than standard berberine) due to its reduced, more lipophilic structure, though it currently has less extensive clinical validation despite promising preliminary research
A 2026 survey from Business Group on Health found that nearly eight in 10 employers said GLP-1s were increasing company healthcare costs, with many weighing stricter coverage rules as medical and pharmacy spending rise
However, average masks the true range: approximately 35% of trial participants lost more than 25% of body weight, while 15% lost less than 15%
Finally, the remaining papers studied patients with alcohol use disorder (2), anorexia nervosa (1), acquired hypothalamic damage (1), Prader-Willi syndrome (1), and major depressive disorder (1)